DDD Related Earnings News
-
Needham & Company Lifts Numbers on 3D Systems (DDD) on Offering, RDPG Deal
-
Solid Q1 Results from Stratasys (SSYS) Pushes 3D Printing Segment Higher (DDD) (XONE)
-
3D Systems (DDD) Steps Closer to Achieving 2013 Guidance
-
3D Systems (DDD) Acquires RPDG, Boosts FY13 Outlook
-
3D Systems Corp. (DDD) Reports In-Line Q1 EPS
-
3D Systems (DDD) to Report Q1 Results April 30th; Street Sees 16% EPS Drop
-
3D Printing Newbie Drives the Group Higher Thursday (XONE) (DDD) (SSYS)
-
3D Systems (DDD) Completes $55M Acquisition of Geomagic; Sees Immediate Accretion
-
UPDATE: 3D Systems (DDD) Tops Q4 EPS by 1c
-
3D Systems (DDD) to Report Q4 Results Feb. 25th; Street Sees 41% EPS Growth
-
3D Systems Corp. (DDD) Tops Q3 EPS by 5c; Boosts FY12 Outlook
-
3D Systems (DDD) to Benefits from Synergies Related to Rapidform Acquisition
-
Stratasys (SSYS) Gets Boost from 3D Systems (DDD) into Q2 Results; Street Sees 39% EPS Growth
-
Needham & Company Maintains a 'Buy' on 3D Systems (DDD); Solid Q2 with Strong Top-Line Growth
-
3D Systems Corp. (DDD) Reports In-Line Q2 EPS; Affirms Outlook
-
Barclays Q2 Preview on U.S. IT Hardware: Caution Should Be the Norm (IBM, XRX, EMC, LXK, AAPL, WDC, IM, DDD, STX)
-
Needham & Company Maintains a 'Buy' on 3D Systems (DDD); Adjusting Estimates for Recent Offering
-
3D Systems Corporation (DDD) Acquires Bespoke Innovations; Affirms Outlook
-
Canaccord Genuity Reiterates a 'Buy' on 3D Systems (DDD); Analyst Day Highlights
-
3D Systems (DDD) Reports Strong Q1 Results; Reaffirms FY12
-
Barclays Maintains an 'Equalweight' on 3D Systems (DDD); Snapping Back in Q4; Updates Guidance
-
Needham & Company Reaffirms a 'Buy' on 3D Systems (DDD); Ends 2011 On Strong Note, With Q4 Upside
-
3D Systems Corp. (DDD) Tops Q4 EPS by 11c; Reaffirms Outlook
-
3D Systems Corp. (DDD) Misses Q3 EPS by 2c, Sales Fall Inline
-
3D Systems Corp. (DDD) Tops Q2 EPS by 11c
-
SCOLR Pharma Inc. (DDD) Posts In-Line Q3 Loss
-
SCOLR Pharma Inc. (DDD) Posts Mixes Q2 Results
-
SCOLR Pharma (DDD) Won't Make Previous FY10 Rev Guidance, Cites Nutritional Product Sales
-
SCOLR Pharma Inc. (DDD) Posts Q1 Loss of $0.02, Narrower than Views; Revs Light
-
SCOLR Pharma (DDD) Reports a Q1 Loss
Back to DDD Stock Lookup
